{
  "story_id": "da8e5d86e7ddacc234e51cfb9e5fd9de",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-01T10:54:26.000Z",
  "content_hash": "1656e0856de9e4e67b3353036985edd33151582e25c01ead75c723cc52b55799",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Medtronic Q1 2027 Revenue Surges 13.7% and Raises Fiscal Guidance",
    "dek": "Medtronic reported $9.8 billion Q1 revenue and raised fiscal 2027 growth guidance amid strong portfolio performance.",
    "prose": "Medtronic plc reported first quarter fiscal 2027 worldwide revenue of $9.8 billion, an increase of 13.7% as reported and 13.7% on an organic basis. [^1]\n\nMedtronic's stock rose 4.8% in pre-market trading to $95 following the release of its first-quarter fiscal 2027 results, compared with a previous close of $90.65. [^2]\n\nMedtronic raised its fiscal 2027 organic revenue growth guidance to a range of 7.25% to 7.75% and diluted non-GAAP EPS guidance to $5.94 to $6.00. [^3]\n\nMedtronic reported GAAP diluted earnings per share of $1.14 and non-GAAP diluted earnings per share of $1.45 for the quarter. [^4]\n\nThe Cardiovascular portfolio revenue increased 18.9% organically, led by 15% growth in Cardiac Rhythm Management and 88% growth in Cardiac Ablation Solutions. [^5]",
    "cited": "[{\"statement\":\"Medtronic plc reported first quarter fiscal 2027 worldwide revenue of $9.8 billion, an increase of 13.7% as reported and 13.7% on an organic basis.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T10:45:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"]},{\"statement\":\"Medtronic's stock rose 4.8% in pre-market trading to $95 following the release of its first-quarter fiscal 2027 results, compared with a previous close of $90.65.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T10:54:26.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"Medtronic raised its fiscal 2027 organic revenue growth guidance to a range of 7.25% to 7.75% and diluted non-GAAP EPS guidance to $5.94 to $6.00.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T10:45:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"]},{\"statement\":\"Medtronic reported GAAP diluted earnings per share of $1.14 and non-GAAP diluted earnings per share of $1.45 for the quarter.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T10:45:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"]},{\"statement\":\"The Cardiovascular portfolio revenue increased 18.9% organically, led by 15% growth in Cardiac Rhythm Management and 88% growth in Cardiac Ablation Solutions.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T10:45:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "8054bc27c7bebe0ca382925ed9cfb242",
      "thread_id": "3b1ed7a8ff446abbe9055c274c950838",
      "thread_label": "Cornerstone Robotics",
      "novelty": "UPDATE",
      "content_hash": "c049da002c4315bbdbfe8edd1cd3c50088f7dc2491a45c7e4d4959367251c95f",
      "last_published_at": "2026-09-01T10:54:26.000Z",
      "read_receipt": {
        "slice_hash": "d4ac0a2f57fe23673b12348e709b1da106e5f699abff4c23e1c028206e3b8aa9",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDFUMTA6MjY6MzUuMDAwMDAwWiIsImlkIjoiNzgyZTZlZjk4ZDcwMDhkYjZkZGI4M2ZhZTUyNDRkMzAiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDFUMTE6MzA6MDAuMDAwMDAwWiIsImlkIjoiNmUwNDI1MjFiN2Q4MmZkMTY3MWM1N2M3MDcxMzU4ZTAiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12017721,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "PQqzLq7NNe8Olj6A0BwqJ7J2g3tloJH0lArCBp-czh8t_MkT0Wj0GBhmKhFoWgetM7H_WCZWBslgi0_EoJ4pAA",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-02T21:11:16.521Z"
  },
  "cited_facts": [
    {
      "statement": "Medtronic plc reported first quarter fiscal 2027 worldwide revenue of $9.8 billion, an increase of 13.7% as reported and 13.7% on an organic basis.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T10:45:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Cision PR Newswire"
      ]
    },
    {
      "statement": "Medtronic's stock rose 4.8% in pre-market trading to $95 following the release of its first-quarter fiscal 2027 results, compared with a previous close of $90.65.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T10:54:26.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "Medtronic raised its fiscal 2027 organic revenue growth guidance to a range of 7.25% to 7.75% and diluted non-GAAP EPS guidance to $5.94 to $6.00.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T10:45:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Cision PR Newswire"
      ]
    },
    {
      "statement": "Medtronic reported GAAP diluted earnings per share of $1.14 and non-GAAP diluted earnings per share of $1.45 for the quarter.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T10:45:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Cision PR Newswire"
      ]
    },
    {
      "statement": "The Cardiovascular portfolio revenue increased 18.9% organically, led by 15% growth in Cardiac Rhythm Management and 88% growth in Cardiac Ablation Solutions.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T10:45:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Cision PR Newswire"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}